Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

Antivascular Therapy via Inhibition of Receptor Tyrosine Kinases in an Orthotopic Murine Model of Salivary Adenoid Cystic Carcinoma

  • Park, Young-Wook (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University) ;
  • Kang, Hye-Jeong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University) ;
  • Park, Jung-Min (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University)
  • Published : 2008.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We evaluated the therapeutic effect of AEE788, a dual inhibitor of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) receptor tyrosine kinases on human salivary adenoid cystic carcinoma (ACC) cells growing in nude mice. Experimental Design: We examined the effects of AEE788 on salivary ACC cell growth and apoptosis. To determine the in vivo effects of AEE788, nude mice with orthotopic parotid tumors were randomized to receive oral AEE788 (50 mg/kg) three times per week, injected paclitaxel ($200{\mu}g$) once per week, AEE788 plus paclitaxel, or placebo. Mechanisms of in vivo AEE788 activity were determined by immunohistochemical analysis. Results: Treatment of salivary ACC cells with AEE788 led to growth inhibition and induction of apoptosis. AEE788 inhibited tumor growth and prevented lung metastasis in nude mice. Furthermore, AEE788 potentiated growth inhibition and apoptosis of ACC tumor cells mediated by paclitaxel. Tumors of mice treated with AEE788 and AEE788 plus paclitaxel exhibited down-regulation of activated EGFR and its downstream mediators (Akt and MAPK), increased tumor and endothelial cell apoptosis, and decreased microvessel den-sity, which correlated with a decrease in the level of MMP-9, MMP-2 and bFGF expression and a decrease in the incidence of vascular metastasis. Conclusions: These data show that tumor-associated endothelial cells are important in the process of tumor-metastasis. And VEGFR can be a molecular target for therapy of metastatic lung lesion of salivary ACC.

Keywords

References

  1. Spiro RH: Salivary neoplasms, overview of a 35 year experience with 2,807 patients. Head Neck Surg 1986;8:177-184 https://doi.org/10.1002/hed.2890080309
  2. Fordice J, Kershaw C, El-Naggar A, Goepfert H: Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 1999;125(2):149-152 https://doi.org/10.1001/archotol.125.2.149
  3. Teo PML, Chan ATC, Lee WY, Leung SF, Chan ESY, Mok CO: Failure patterns and factors affecting prognosis of salivary gland carcinoma: retrospective study. HKMJ 2000;6(1):29-36
  4. Park YW: Cellular and molecular characterization of adenoid cystic carcinoma of the salivary glands. J Kor Maxillofac Plast Reconst Surg 2005;27(2):110-122
  5. Park YW, Kim JH: Immunohistochemical assays for the expression of epidermal growth factor-signaling proteins in adenoid cystic carcinomas of human salivary glands. J Kor Maxillofac Plast Reconst Surg 2006;28(6):499-510
  6. Kim HS, Kim SM, Park YW: Immunohistochemical study on expression patterns of tumor growth related factors in salivary glands tumors. J Kor Maxillofac Plast Reconst Surg 2007;29(5):405-416
  7. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S: Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 2000;86:307-317 https://doi.org/10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I
  8. El-Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 2004;91:418-424 https://doi.org/10.1038/sj.bjc.6601921
  9. Khazaie K, Schirrmacher V, Lichtner RB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993;12:255-274 https://doi.org/10.1007/BF00665957
  10. Kuan CT, Wikstrand CJ, Bigner DD: EGF mutant receptor VIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96 https://doi.org/10.1677/erc.0.0080083
  11. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C et al: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHBEGF. Nature 1999;402:884-888 https://doi.org/10.1038/47260
  12. Alroy I, Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83-86 https://doi.org/10.1016/S0014-5793(97)00412-2
  13. Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014 https://doi.org/10.1146/annurev.biochem.68.1.965
  14. Yarden Y, Sliwkowski M: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137 https://doi.org/10.1038/35052073
  15. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1997;74:49-139
  16. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase-Akt pathway in human cancer. Nat Rev Cancer 2002;2:489-501 https://doi.org/10.1038/nrc839
  17. Myoken Y, Myoken Y, Okamoto T, Sato JD, Kan M, McKEEHAN WL: Immunohistochemical study of overexpression of fibroblast growth Factor-1(FGT-1), FGT-2, and FGT Receptor-1 in human malignant salivary gland tumours. J Pathol 1996;178:429-436 https://doi.org/10.1002/(SICI)1096-9896(199604)178:4<429::AID-PATH495>3.0.CO;2-1
  18. Ishibashi H, Shiratuchi T, Nakagawa K, Onimaru M, Sugiura T, Sueishi K et al: Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol 2001;37(1):77-83 https://doi.org/10.1016/S1368-8375(00)00062-2
  19. Nagel H, Laskawi R, Wahlers A, Hemmerlein B: Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathol 2004;44:222-231 https://doi.org/10.1111/j.0309-0167.2004.01814.x
  20. Park YW, In YS: Immunohistochemical assays for the expression of angiogenic signaling molecules and microvessel density in adenoid cystic carcinomas of human salivary glands. J Kor Oral Maxillofac Surg 2006;32(6):530-543
  21. In YS, Kim SM, Park YW: Comparative immunohistochemical assays for the expression of angiogenic factors in tumors of human salivary glands. J Kor Maxillofac Plast Reconst Surg 2007;29(1):10-23
  22. Jang JH, Kwon KJ, Park YW: Expressions of vascular metastasis related factors in murine orthotopic tumor models of salivary glands. J Kor Maxillofac Plast Reconst Surg 2007;29(6):499-508
  23. Yu F, Jiang XZ, Chen WT, Zhao YF, Zhou XJ: Microvessel density and expression of vascular endothelial growth factor in adenoid cystic carcinoma of salivary gland. Shanghai Kou Qiang Yi Xue 2003;12(6):443-446
  24. Perrot E, Davy N, Poubeau P, Arvin-Berod C: Chemotherapy with paclitaxel for lung metastases of cystic adenoidcarcinoma. A case report and review of the literature. Rev Pneumol Clin 2003;59(6):371-374
  25. Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G: Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000;20(5C):3781-3783
  26. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ et al: Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 2002;8:2413-2422
  27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 https://doi.org/10.1056/NEJMoa040938
  28. Chung SH, Park YW: An experimental study for establishment of orthotopic salivary tumor models in mice. J Kor Oral Maxillofac Surg 2007;33(2):81-93
  29. Friedman EW, Schwartz AE: Diagnosis of salivary gland tumors. Cancer 1974;24:266-273 https://doi.org/10.1002/1097-0142(196908)24:2<266::AID-CNCR2820240209>3.0.CO;2-#
  30. Craven RJ, Lightfoot H, Cance WG: A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol 2003;12:39-49 https://doi.org/10.1016/S0960-7404(03)00004-5
  31. Castilla MA, Neria F, Renedo G, Pereira DS, Gonzalez-Pacheco FR, Jimenez S et al: Tumor-induced endothelial cell activation: role of vascular endothelial growth factor. Am J Physiol Cell Physiol 2004;286(5):C1170-1176 https://doi.org/10.1152/ajpcell.00306.2003
  32. Chang C, Werb Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends in Cell Biol 2001;11(11):S37-43 https://doi.org/10.1016/S0962-8924(01)82222-4
  33. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744 https://doi.org/10.1038/35036374
  34. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R et al: Angiogenesis and progressive growth of human ovarian carcinoma is dependent on host metalloproteinase-9. J Natl Cancer (in press)
  35. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM: Interleukin-8 as a macrophage derived mediator of angiogenesis. Science 1992;258:1798-1801 https://doi.org/10.1126/science.1281554
  36. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-270 https://doi.org/10.1016/0167-5699(92)90008-U
  37. Sunderkkotter C, Steinbrink K, Goebeler M, Bhardwag R, Sorg C: Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422 https://doi.org/10.1002/jlb.55.3.410
  38. Donaldson KL, Goolsby GL, Wahl AF: Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int J Cancer 1994;57:847-855 https://doi.org/10.1002/ijc.2910570614
  39. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6(5):2053-2063
  40. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA et al: Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003;9(8):3183-3189
  41. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M: ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 2004;10(2):794-801 https://doi.org/10.1158/1078-0432.CCR-0948-03